A Review on the Complications and Management of Osteoporosis
Article Sidebar
-
Osteoporosis, Osteoporosis Management, Bone Mineral Density, Fracture Risk Management
Abstract
Osteoporosis is a skeletal disease that is characterized by low bone mineral density. It also disrupts the microarchitectural of the bone. In leads to increased bone fragility and risk of fractures. Even while it occurs in persons of various ages and ethnicities (including Caucasians and whites), it is more common among Caucasians (whites), elderly people, and women. Osteoporosis is becoming a global epidemic as the world's population ages and lives longer. Osteoporosis affects an estimated 200 million individuals worldwide. It affects a 3rd of women and one in every 12 men. This increases morbidity as well as mortality due to several complications. Thus, it is essential to improve diagnostic methods and to introduce early intervention to prevent this disease. Lifestyle modification is an important recommendation for the population at risk. There are several pharmacological interventions that could be taken to prevent osteoporosis as vitamin D and calcium supplements and to treat osteoporosis as bisphosphonates and anabolic drugs. The most important step in the treatment is tailored to the individual patients and to optimize the treatment according to each case individually. Therefore, increasing doctor awareness, which promotes improved awareness among the general public, will be useful in averting this epidemic.
Full text article
References
Bischoff-Ferrari, H. A., Willett, W. C., Wong, J. B., Giovannucci, E., Dietrich, T., Dawson-Hughes, B. 2005. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA, 293(18):2257–2264.
Black, D. M., Cummings, S. R., Karpf, D. B. 1996. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 348(9041):1535–1541.
Bone, H. G., Hosking, D., Devogelaer, J. P., Tucci, J. R., Emkey, R. D., Tonino, R. P. 2004. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med, 350(12):1189–1199.
Brown, J. P., Josse, R. G. 2002. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ, 167(10):1–34.
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., Tosteson, A. 2007. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res, 22(3):465–475.
Center, J. R., Nguyen, T. V., Schneider, D., Sambrook, P. N., Eisman, J. A. 1999. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet, 353(9156):878–882.
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A. 2004. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 19(8):1241–1249.
Compston, J., Bowring, C., Cooper, A., Cooper, C., Davies, C., Francis, R. 2013. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas, 75(4):392–398.
Compston, J., Cooper, A., Cooper, C. 2009. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas, 62(2):105–108.
Cooper, C., Melton, L. J. 1992. 3rd Epidemiology of osteoporosis. Trends Endocrinol Metab, 3(6):224–229.
Cummings, S. R., Bates, D., Black, D. M. 2002. Clinical use of bone densitometry: scientific review. JAMA, 288(15):1889–1897.
Cummings, S. R., Black, D. M., Thompson, D. E. 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 280(24):2077–2082.
Daddona, P. E., Matriano, J. A., Mandema, J., Maa, Y. F. 2011. Parathyroid Hormone (1-34)-Coated Microneedle Patch System: Clinical Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis. Pharm Res, 28(1):159–165.
Dawson-Hughes, B., Bischoff-Ferrari, H. A., Willett, W. C., Staehelin, H. B., Bazemore, M. G., Zee, R. Y. 2004. Effect of Vitamin D on falls: a meta-analysis. JAMA, 291(16):1999–2006.
Ensrud, K. E., Ewing, S. K., Taylor, B. C., Fink, H. A., Stone, K. L., Cauley, J. A. 2007. Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci, 62(7):744–751.
Harris, S. T., Watts, N. B., Genant, H. K. 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA, 282(14):1344–1352.
Hodgson, S. F., Watts, N. B., Bilezikian, J. P. 2003. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract, 9(6):544–564.
Kanis, J. A. 2002. Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359(9321):1929–1936.
Kanis, J. A., Johnell, O., Laet, D., Johansson, C., Oden, H., Delmas, A., P 2004. A meta-analysis of previous fracture and subsequent fracture risk. Bone, 35(2):375–382.
Kanis, J. A., Mccloskey, E. V., Johansson, H., Strom, O., Borgstrom, F., Oden, A. 2008. Case is finding for the management of osteoporosis with FRAX®–assessment and intervention thresholds for the UK. Osteoporos Int, 19(10):1395–1408.
Mcclung, M. R., Geusens, P., Miller, P. D. 2001. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 344(5):333–340.
Melton, L. J., Achenbach, S. J., Atkinson, E. J., Therneau, T. M., Amin, S. 2013. Long-term mortality following fractures at different skeletal sites: a population-based cohort study. Osteoporos Int, 24(5):1689–1696.
Melton, L. J., Chrischilles, E. A., Cooper, C., Lane, A. W., Riggs, B. L. 1992. Perspective. How many women have osteoporosis? J Bone Miner Res, 7(9):1005–1010.
Moyer, V. A. 2013. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 158(9):691–697.
NIH Consensus Development Panel 2001. Osteoporosis prevention, diagnosis, and therapy. JAMA, 285(6):785–795.
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S. 2010. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ, 182(17):1864–1873.
Ray, N. F., Chan, J. K., Thamer, M., Melton, L. J. 1997. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res, 12(1):24–35.
Ross, A. C., Taylor, C. L., Yaktine, A. L. 2011. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC). US National Academies Press. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D. 2010. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 25(11):2267–2294.
Siminoski, K., Warshawski, R. S., Lee, J. H., K 2006. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. Osteoporos Int, 17(2):290–296.
Siris, E. S., Harris, S. T., Eastell, R., Zanchetta, J. R., Goemaere, S., Diez-Perez, A. 2005. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (Core) study. J Bone Miner Res, 20(9):1514–1524.
Tannenbaum, C., Clark, J., Schwartzman, K., Wallenstein, S., Lapinski, R., Meier, D. 2002. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab, 87(10):4431–4438.
Unnanuntana, A., Gladnick, B. P., Donnelly, E., Lane, J. M. 2010. The assessment of fracture risk. J Bone Joint Surg Am, 92(3):743–753.
Vasikaran, S., Eastell, R., Bruyere, O., Foldes, A. J., Garnero, P., Griesmacher, A. 2011. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int., 22(2):391–420.
Vestergaard, P., Rejnmark, L., Mosekilde, L. 2005. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int, 16:134–141.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.